Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2013

View Archived Issues

A report on the discovery of a novel host-specific biomarker for river blindness

Venaxis enters commercial development agreements for its appendicitis test

FDA grants 6-month pediatric exclusivity to Hospira's Precedex injection

FDA grants fast track status to TransTech Pharma's TTP-488

Addex receives Michael J. Fox Foundation grant for dipraglurant

Boehringer Ingelheim and Lilly commence MARLINA trial

Initial results from phase II BOLD extension study of siponimod presented

Acumen Pharmaceuticals describes antibody that binds soluble beta-amyloid oligomers

Italian and U.S. scientists divulge novel FAAH inhibitors

Targacept identifies anti-inflammatory therapeutics

InSite Vision reports phase III BromSite data

Merck Serono and Bristol-Myers Squibb to promote Glucophage in China

Novel ciclosporin derivatives described

Trevena reports first-in-human data on TRV-130

NPS Pharmaceuticals regains rights to teduglutide and PTH 1-84

Pharmaxis receives FDA complete response letter for Bronchitol

Canadian researchers patent new cancer diagnostics

Novel tyrosine kinase inhibitors patented

HLA-A-based peptide immunotherapies under investigation for prostate cancer

Affymetrix QuantiGene Technology used to assess microRNA 122 as hepatotoxicity biomarker

Pharmacokinetic evaluation of a novel intrathecal-lumbar formulation of idursulfase

Biocancell's phase IIb trial in bladder cancer meets primary endpoint

EGEN initiates phase I trial in recurrent ovarian cancer

Phase III study of Amgen's talimogene laherparepvec meets primary endpoint

AstraZeneca reports plans to restructure its global R&D operations

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...